Neurotensin receptor

Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer

Retrieved on: 
Monday, November 7, 2022
Employment, Board, DNA, FGFR3, Merck, TRIUMF, Neoplasm, Acquisition, Neurotensin receptor, Isotope, View, AstraZeneca, Cancer, Radiopharmaceutical, IND, Financial compensation, Multimedia, Tesaro, TAT, NTSR1, Leadership, Regeneron Pharmaceuticals, Pembrolizumab, Patient, Corporate communication, Clinical trial, Tat, FDA, Pharmaceutical industry, Checkmate, Sanofi, Fusion

HAMILTON, ONandBOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.

Key Points: 
  • HAMILTON, ONandBOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.
  • Dr. Bobilev joins Fusion from Checkmate Pharma, where he was vice president, head of clinical development until the company's acquisition by Regeneron earlier in 2022.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA (pembrolizumab) in patients with solid tumors expressing IGF-1R.

Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 7, 2022
AstraZeneca, Tat, DNA, IND, View, Neurotensin receptor, Morgan, NTSR1, TRIUMF, Isotope, Multimedia, Pembrolizumab, Corporate communication, Conference, Company, FDA, Neoplasm, Merck, Webcast, FGFR3, Patient, Pharmaceutical industry, Fusion

HAMILTON, ON and BOSTON, Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference onWednesday, September 14, 2022at12:55 p.m.

Key Points: 
  • HAMILTON, ON and BOSTON, Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference onWednesday, September 14, 2022at12:55 p.m.
  • A replay of the webcast will be archived on the Company's website for 60 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

Retrieved on: 
Tuesday, June 14, 2022
Pembrolizumab, Antibody, SNMMI, Half-life, Review, Security (finance), Dosimetry, AstraZeneca, COVID-19, GMP, U.S. Securities and Exchange Commission, Safety, Toxicity, Therapeutic index, Neurotensin receptor, McMaster University, Society, View, Liver, Lymph, Fusion, Tat, Company, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Pharmacokinetics, Forward-looking statement, Research, Private Securities Litigation Reform Act, Isotope, Merck, DNA, Neoplasm, Disease, Lung, IND, SEC, Radiopharmaceutical, FGFR3, Society of Nuclear Medicine and Molecular Imaging, Coronavirus, Molecular imaging, Multimedia, Good manufacturing practice, Annual general meeting, NTSR1, Actinium-225, Medical imaging, Vaccine, Pharmaceutical industry, Patient

HAMILTON, ON and BOSTON, June 14, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of imaging data from the "cold antibody sub-study" evaluating pre-administration of cold antibody (naked antibody without the isotope) prior to administration of the imaging agent (antibody with the isotope) in the Phase 1 study of FPI-1434 for the treatment of solid tumors expressing IGF-1R. Data were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting in a presentation titled "Impact of Pre-Administration of Anti-IGF-1R Antibody FPI-1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In]-FPI-1547 in Patients with Solid Tumors".

Key Points: 
  • The cold antibody sub-study was conducted concurrently with the dose escalation portion of the Phase 1 study of FPI-1434 for the treatment of solid tumors.
  • Imaging data from the study demonstrate a favorable gain in [111In]-FPI-1547 tumor lesion uptake versus normal tissue when FPI-1175 was pre-administered and compared to dosing with FPI-1547 alone.
  • Dr. Valliant continued, "These data from the cold antibody sub-study strengthen our understanding of this dosing regimen and support further evaluation.
  • As a result, Fusion encourages investors, media and others interested to review the information that Fusion posts there on a regular basis.

Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement

Retrieved on: 
Friday, June 10, 2022
DNA, Good manufacturing practice, National Nuclear Energy Commission, Company, DNA-directed RNA interference, FGFR3, Alpha, NTSR1, Neurotensin receptor, Radionuclide, Partnership, Private Securities Litigation Reform Act, DOE, GMP, Actinium, IND, NRC, Isotope, Neoplasm, U.S. Department of Defense Strategy for Operating in Cyberspace, Radium, Pembrolizumab, FDA, Risk, Tat, Patient, National Nuclear Security Administration, U.S. Department of Energy, Office of Inspector General, AstraZeneca, Technology, SEC, Merck, Actinium-225, Nuclear medicine, TRIUMF, McMaster University, University, India–Singapore Comprehensive Economic Cooperation Agreement, Uranium, Lithium, Pharmaceutical industry, Fusion

As part of the agreement, Fusion will also have an option to invest in future production of actinium-225 to scale with Fusion's needs.

Key Points: 
  • As part of the agreement, Fusion will also have an option to invest in future production of actinium-225 to scale with Fusion's needs.
  • Fusion currently has existing actinium supply arrangements with TRIUMF and the U.S. Department of Energy (DOE).
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Niowave is a Cooperative Agreement partner with the National Nuclear Security Administration to develop a domestic supply of molybdenum-99 and currently produces yttrium-90 for use in cancer therapy.

Fusion Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Retrieved on: 
Monday, June 6, 2022
DNA, View, Good manufacturing practice, Company, Conference, FGFR3, NTSR1, Neurotensin receptor, Corporate communication, Webcast, GMP, Neoplasm, U.S. Department of Commerce Office of Security, IND, Multimedia, Isotope, Pembrolizumab, Tat, Patient, U.S. Department of Energy, Office of Inspector General, AstraZeneca, Merck, TRIUMF, McMaster University, Pharmaceutical industry, Fusion

HAMILTON, ONandBOSTON, June 6, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference in New York, New York onFriday, June 10, 2022at10:30 a.m.

Key Points: 
  • HAMILTON, ONandBOSTON, June 6, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference in New York, New York onFriday, June 10, 2022at10:30 a.m.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.
  • For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, [email protected]
    View original content to download multimedia: https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-prese...

Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day

Retrieved on: 
Wednesday, May 11, 2022
Company, Good manufacturing practice, Neoplasm, GMP, FGFR3, Webcast, Multimedia, Patient, View, Corporate communication, Radiopharmaceutical, Merck, Tat, IND, Pembrolizumab, Neurotensin receptor, NTSR1, DNA, Isotope, AstraZeneca, Pharmaceutical industry, Fusion

HAMILTON, ONandBOSTON, May 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the Guggenheim Securities Radiopharmaceuticals Day in New York, New York onTuesday, May 17, 2022at3:00 p.m.

Key Points: 
  • HAMILTON, ONandBOSTON, May 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the Guggenheim Securities Radiopharmaceuticals Day in New York, New York onTuesday, May 17, 2022at3:00 p.m.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.
  • For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, [email protected]
    View original content to download multimedia: https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-prese...

Oxford Finance Announces the Closing of a $75 Million Credit Facility With Fusion Pharmaceuticals

Retrieved on: 
Tuesday, April 5, 2022
Science, Other Science, Radiology, Pharmaceutical, Finance, Oncology, Health, Professional Services, Company, Cancer, Good manufacturing practice, NASDAQ, FGFR3, Oxford, IND, Fusion, NTSR1, Merck, Neoplasm, AstraZeneca, DNA, Tat, McMaster University, Neurotensin receptor, Solution, Isotope, Finance, GMP, Patient, Pembrolizumab, Radiation, Pharmaceutical industry, Medical imaging, OXFORD FINANCE LLC, FUSION PHARMACEUTICALS, INC.

Proceeds from the transaction will be used for general working capital and to fund the advancement of the Companys pipeline.

Key Points: 
  • Proceeds from the transaction will be used for general working capital and to fund the advancement of the Companys pipeline.
  • We are happy to partner with Fusion, and support its diversified pipeline focused on addressing the unmet needs in cancer treatment.
  • Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, March 24, 2022
Company, Corporate communication, Good manufacturing practice, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., FGFR3, Compugen (Israeli company), Multimedia, Board, IND, NTSR1, Merck, Neoplasm, Board of directors, AstraZeneca, DNA, View, Tat, McMaster University, Neurotensin receptor, Isotope, GMP, Patient, Pembrolizumab, Pharmaceutical industry, Fusion

The stock options were granted as an inducement material to the individual becoming an employee of Fusion in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options were granted as an inducement material to the individual becoming an employee of Fusion in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.
  • For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, [email protected]
    View original content to download multimedia: https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announce...

Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference

Retrieved on: 
Monday, February 28, 2022
Neurotensin receptor, GMP, Tat, DNA, Webcast, Corporate communication, Neoplasm, Company, Multimedia, IND, Isotope, View, Good manufacturing practice, Conference, NTSR1, Patient, Merck, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., McMaster University, AstraZeneca, Pembrolizumab, FGFR3, Pharmaceutical industry, Online shopping, Fusion

HAMILTON, ON and BOSTON, Feb. 28, 2022 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 12:50 p.m.

Key Points: 
  • HAMILTON, ON and BOSTON, Feb. 28, 2022 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 12:50 p.m.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.
  • Fusion Contact: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, [email protected]
    View original content to download multimedia: https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-parti...

Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference

Retrieved on: 
Friday, January 21, 2022
NTSR1, Webcast, Patient, Tat, Conference, Neurotensin receptor, Isotope, Pembrolizumab, Merck, IND, GMP, View, AstraZeneca, Good manufacturing practice, FGFR3, Company, Multimedia, Neoplasm, McMaster University, DNA, Online shopping, Pharmaceutical industry, Fusion

HAMILTON, ONandBOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m.

Key Points: 
  • HAMILTON, ONandBOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m.
  • A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA (pembrolizumab) in patients with solid tumors expressing IGF-1R.